Considering the dilemma of the general concept that highly activated Akt promotes tumorigenesis and our data implying that low Akt activity maintains the homeostasis of CSCs, it should be beneficial to apply Akt inhibitors to limit Akt activity under control in cancer treatment. The gene discussed is AKT1; the disease is cancer.